Vyome Holdings Inc (HIND)

$1.95 -0.06 (-2.99%)
Market Cap 14.11M
Revenue (ttm) 320,000.00
Net Income (ttm) -10.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,206.25%
Debt to Equity Ratio 0.00
Volume 5,400
Avg Vol 10,004
Day's Range N/A - N/A
Shares Out 7.02M
Stochastic %K 0%
Beta 1.50
Analysts Strong Sell
Price Target $8.83

Company Profile

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop i...

Industry: Biotechnology
Sector: Healthcare
Phone: 973 832 8147
Address:
Harvard Square, One Mifflin Place Suite 400, Cambridge, United States
focafoca99
focafoca99 Sep. 14 at 12:25 PM
$HIND brings a seasoned finance leader as new CFO Jerry Leonard. https://www.rapidticker.com/news/hind-vyome-appoints-experienced-public-company-af275c
0 · Reply
focafoca99
focafoca99 Aug. 28 at 10:41 PM
$HIND hired Jerry Leonard as its new chief financial officer, effective Sept. 1. https://www.rapidticker.com/news/hind-sec-filing-425879
0 · Reply
focafoca99
focafoca99 Aug. 25 at 12:36 PM
$HIND detailed its Q2 2026 results, noting VT-1953 progress and a debt-free balance sheet. https://www.rapidticker.com/news/hind-vyome-holdings-reports-second-quarter-dc920e
0 · Reply
bitcoinboombust
bitcoinboombust Aug. 19 at 6:48 PM
$HIND Sales in China with approvel of patent? Hopefully
0 · Reply
moboala
moboala Aug. 19 at 5:13 PM
$HIND is this the break we were looking for?
0 · Reply
Breton2018
Breton2018 Jul. 3 at 11:03 AM
$HIND Need breakout
0 · Reply
BongJamesBong
BongJamesBong Jul. 1 at 4:04 PM
$HIND https://finance.yahoo.com/healthcare/articles/vyome-granted-chinese-patent-strengthening-120000475.html
0 · Reply
CoralC
CoralC Jul. 1 at 1:30 PM
$HIND — Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio https://finance.yahoo.com/healthcare/articles/vyome-granted-chinese-patent-strengthening-120000475.html
0 · Reply
focafoca99
focafoca99 Jul. 1 at 12:33 PM
$HIND captured a new Chinese patent for its besifloxacin acne gel. https://www.rapidticker.com/news/hind-vyome-granted-chinese-patent-strengthening-516409
0 · Reply
STACKD0E
STACKD0E Jul. 1 at 12:10 PM
$LGO $BTQ $ALM $HIND $EVAX ✨️
0 · Reply
Latest News on HIND
Vyome appoints Leonard as Chief Financial Officer

2026-09-14T12:11:53.000Z - 2 days ago

Vyome appoints Leonard as Chief Financial Officer

Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer

Sep 14, 2026, 8:00 AM EDT - 2 days ago

Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer

Vyome initiated with a Buy at Chardan

2026-09-03T09:05:14.000Z - 13 days ago

Vyome initiated with a Buy at Chardan

Vyome names Jerry Leonard as CFO

2026-08-28T20:45:14.000Z - 19 days ago

Vyome names Jerry Leonard as CFO

Vyome reports Q2 EPS (10c)

2026-08-25T12:20:23.000Z - 22 days ago

Vyome reports Q2 EPS (10c)

Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet

Aug 25, 2026, 8:00 AM EDT - 22 days ago

Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet

Vyome Holdings Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 5 weeks ago

Vyome Holdings Quarterly report: Q2 2026

Vyome Holdings Earnings release: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 5 weeks ago

Vyome Holdings Earnings release: Q2 2026

Vyome announces CNIPA granted patent covering formula related to besifloxacin

2026-07-01T12:10:37.000Z - 2 months ago

Vyome announces CNIPA granted patent covering formula related to besifloxacin

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Jul 1, 2026, 8:00 AM EDT - 2 months ago

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Vyome Holdings Earnings Call Transcript: Q1 2026

Jun 3, 2026, 11:00 AM EDT - 3 months ago

Vyome Holdings Earnings Call Transcript: Q1 2026

Vyome Holdings Quarterly report: Q1 2026

Jun 3, 2026, 11:00 AM EDT - 3 months ago

Vyome Holdings Quarterly report: Q1 2026

Vyome Holdings Earnings release: Q1 2026

Jun 3, 2026, 11:00 AM EDT - 3 months ago

Vyome Holdings Earnings release: Q1 2026

Vyome reports Q1 EPS (15c) vs. ($761.59) last year

2026-05-28T13:02:13.000Z - 3 months ago

Vyome reports Q1 EPS (15c) vs. ($761.59) last year

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

May 28, 2026, 8:00 AM EDT - 3 months ago

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

Vyome signs exclusive license agreement with Impetis

2026-05-12T16:18:22.000Z - 4 months ago

Vyome signs exclusive license agreement with Impetis

Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

May 12, 2026, 8:00 AM EDT - 4 months ago

Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

Vyome initiated with a Buy at Litchfield Hills

2026-05-04T11:39:34.000Z - 4 months ago

Vyome initiated with a Buy at Litchfield Hills

Vyome Holdings presents Phase 2 study results on VT-1953

2026-04-22T12:37:23.000Z - 4 months ago

Vyome Holdings presents Phase 2 study results on VT-1953

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

Vyome Holdings to present Phase 2 data on VT-1953 at AACR 2026

2026-04-06T12:44:43.000Z - 5 months ago

Vyome Holdings to present Phase 2 data on VT-1953 at AACR 2026

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

Apr 6, 2026, 8:00 AM EDT - 5 months ago

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

Vyome Holdings Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Vyome Holdings Proxy statement: Proxy filing

Vyome Holdings reports FY25 revenue $319.7k vs $246.9k last year

2026-03-26T12:06:47.000Z - 5 months ago

Vyome Holdings reports FY25 revenue $319.7k vs $246.9k last year

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Vyome Holdings Proxy statement: Proxy filing

Mar 20, 2026, 7:00 AM EDT - 6 months ago

Vyome Holdings Proxy statement: Proxy filing

Vyome Holdings Annual report: Q4 2025

Mar 18, 2026, 7:00 AM EDT - 6 months ago

Vyome Holdings Annual report: Q4 2025

Vyome Holdings publishes preclinical VT-1908 data

2026-02-18T14:11:39.000Z - 7 months ago

Vyome Holdings publishes preclinical VT-1908 data

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Feb 18, 2026, 9:00 AM EST - 7 months ago

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Feb 11, 2026, 7:00 AM EST - 7 months ago

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Vyome Holdings funds budget for VT-1953 study

2026-02-02T12:16:04.000Z - 7 months ago

Vyome Holdings funds budget for VT-1953 study

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Feb 2, 2026, 7:00 AM EST - 7 months ago

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Jan 27, 2026, 8:00 AM EST - 7 months ago

Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Dec 22, 2025, 8:00 AM EST - 8 months ago

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints

2025-12-08T13:20:46.000Z - 9 months ago

Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

Dec 8, 2025, 8:00 AM EST - 9 months ago

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Nov 25, 2025, 7:00 AM EST - 9 months ago

Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Vyome Holdings Earnings Call Transcript: Q3 2025

Nov 20, 2025, 10:00 AM EST - 10 months ago

Vyome Holdings Earnings Call Transcript: Q3 2025

Vyome Holdings Earnings release: Q3 2025

Nov 20, 2025, 10:00 AM EST - 10 months ago

Vyome Holdings Earnings release: Q3 2025

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Nov 18, 2025, 7:00 AM EST - 10 months ago

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Vyome Holdings files to sell 610K shares of common stock for holders

2025-11-06T21:25:52.000Z - 10 months ago

Vyome Holdings files to sell 610K shares of common stock for holders

Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation

Nov 5, 2025, 10:13 AM EST - 10 months ago

Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation

RSLS

Vyome Holdings Announces Results of Annual Shareholder Meeting

Nov 4, 2025, 9:04 AM EST - 10 months ago

Vyome Holdings Announces Results of Annual Shareholder Meeting

Vyome Holdings Proxy statement: Proxy Filing

Oct 6, 2025, 8:00 AM EDT - 11 months ago

Vyome Holdings Proxy statement: Proxy Filing

Vyome Holdings upgraded to Buy at Maxim on immuno-inflammatory pipeline

2025-10-02T12:55:32.000Z - 11 months ago

Vyome Holdings upgraded to Buy at Maxim on immuno-inflammatory pipeline

Vyome Holdings upgraded to Buy from Hold at Maxim

2025-10-02T11:40:07.000Z - 11 months ago

Vyome Holdings upgraded to Buy from Hold at Maxim

Vyome Holdings acquires MIT AI spinout Oculo Health

2025-09-29T11:35:05.000Z - 11 months ago

Vyome Holdings acquires MIT AI spinout Oculo Health

Vyome Holdings Acquires MIT AI Spinout Oculo Health

Sep 29, 2025, 7:00 AM EDT - 11 months ago

Vyome Holdings Acquires MIT AI Spinout Oculo Health

Vyome Stock (HIND) Rockets on Uveitis Study Data

2025-09-17T12:54:52.000Z - 12 months ago

Vyome Stock (HIND) Rockets on Uveitis Study Data

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Sep 17, 2025, 7:00 AM EDT - 12 months ago

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Sep 9, 2025, 8:30 AM EDT - 1 year ago

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

Sep 4, 2025, 8:30 AM EDT - 1 year ago

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio

Aug 21, 2025, 7:00 AM EDT - 1 year ago

Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio

Vyome Announces Strategic Review of Livechain (OTCID: LICH)

Aug 18, 2025, 8:30 AM EDT - 1 year ago

Vyome Announces Strategic Review of Livechain (OTCID: LICH)

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Aug 15, 2025, 8:00 AM EDT - 1 year ago

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

Aug 14, 2025, 7:18 PM EDT - 1 year ago

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

RSLS

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

Aug 13, 2025, 11:50 AM EDT - 1 year ago

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

RSLS

Vyome Announces New Board of Directors with Deep MIT and AI Ties

Aug 12, 2025, 9:48 AM EDT - 1 year ago

Vyome Announces New Board of Directors with Deep MIT and AI Ties

RSLS

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

Aug 7, 2025, 5:01 PM EDT - 1 year ago

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

RSLS

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Jul 24, 2025, 4:39 PM EDT - 1 year ago

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

RSLS

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

Jul 22, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

RSLS

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

Jul 21, 2025, 2:10 PM EDT - 1 year ago

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

RSLS

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

Jul 1, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

RSLS

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

Jun 27, 2025, 9:01 AM EDT - 1 year ago

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

RSLS

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

Jun 26, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

RSLS

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

Jun 25, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

Jun 12, 2025, 8:25 AM EDT - 1 year ago

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

RSLS

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

Jun 9, 2025, 9:00 AM EDT - 1 year ago

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

RSLS

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

Jun 3, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

RSLS

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

May 21, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

RSLS

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

May 7, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

RSLS

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

May 2, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

RSLS

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

Apr 28, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

RSLS

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Apr 21, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

Apr 9, 2025, 4:05 PM EDT - 1 year ago

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

RSLS

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

Apr 7, 2025, 4:05 PM EDT - 1 year ago

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

RSLS

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

Mar 21, 2025, 11:35 AM EDT - 1 year ago

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

RSLS

Vyome Holdings Proxy statement: Proxy Filing

Mar 14, 2025, 8:00 AM EDT - 1 year ago

Vyome Holdings Proxy statement: Proxy Filing

Vyome Holdings Proxy statement: Proxy Filing

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Vyome Holdings Proxy statement: Proxy Filing

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Mar 10, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS

Vyome Holdings Proxy statement: Proxy Filing

Mar 3, 2025, 7:00 AM EST - 1 year ago

Vyome Holdings Proxy statement: Proxy Filing

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

Feb 25, 2025, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

RSLS

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

Feb 15, 2025, 11:17 PM EST - 1 year ago

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

RSLS

focafoca99
focafoca99 Sep. 14 at 12:25 PM
$HIND brings a seasoned finance leader as new CFO Jerry Leonard. https://www.rapidticker.com/news/hind-vyome-appoints-experienced-public-company-af275c
0 · Reply
focafoca99
focafoca99 Aug. 28 at 10:41 PM
$HIND hired Jerry Leonard as its new chief financial officer, effective Sept. 1. https://www.rapidticker.com/news/hind-sec-filing-425879
0 · Reply
focafoca99
focafoca99 Aug. 25 at 12:36 PM
$HIND detailed its Q2 2026 results, noting VT-1953 progress and a debt-free balance sheet. https://www.rapidticker.com/news/hind-vyome-holdings-reports-second-quarter-dc920e
0 · Reply
bitcoinboombust
bitcoinboombust Aug. 19 at 6:48 PM
$HIND Sales in China with approvel of patent? Hopefully
0 · Reply
moboala
moboala Aug. 19 at 5:13 PM
$HIND is this the break we were looking for?
0 · Reply
Breton2018
Breton2018 Jul. 3 at 11:03 AM
$HIND Need breakout
0 · Reply
BongJamesBong
BongJamesBong Jul. 1 at 4:04 PM
$HIND https://finance.yahoo.com/healthcare/articles/vyome-granted-chinese-patent-strengthening-120000475.html
0 · Reply
CoralC
CoralC Jul. 1 at 1:30 PM
$HIND — Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio https://finance.yahoo.com/healthcare/articles/vyome-granted-chinese-patent-strengthening-120000475.html
0 · Reply
focafoca99
focafoca99 Jul. 1 at 12:33 PM
$HIND captured a new Chinese patent for its besifloxacin acne gel. https://www.rapidticker.com/news/hind-vyome-granted-chinese-patent-strengthening-516409
0 · Reply
STACKD0E
STACKD0E Jul. 1 at 12:10 PM
$LGO $BTQ $ALM $HIND $EVAX ✨️
0 · Reply
bitcoinboombust
bitcoinboombust Jun. 11 at 9:21 PM
$HIND
0 · Reply
resistancebreakers
resistancebreakers Jun. 11 at 8:50 AM
$HIND
0 · Reply
thedavidsonny
thedavidsonny Jun. 10 at 2:41 PM
XOS 🔥 🔥 🔥 🔥 🔥 🔥 $HEXO $H $HCMC $HD $HIMS $HIND
0 · Reply
thedavidsonny
thedavidsonny Jun. 9 at 10:39 PM
$AAPL $META $TSLA $SPACZZX.P $SPCE $HIND $OKLO $YINN
0 · Reply
thedavidsonny
thedavidsonny Jun. 9 at 10:21 PM
$AAPL $META $TSLA $SPACZZX.P $SPCE $HIND $OKLO $YINN
0 · Reply
thedavidsonny
thedavidsonny Jun. 9 at 10:07 PM
YYGH ON 🔥 $AAPL $META $TSLA $SPACZZX.P $SPCE $HIND $OKLO $YINN
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Jun. 3 at 1:00 PM
$HIND Q1 '26 Earnings Results & Recap Vyome reported a net loss of approximately $963,000, or $0.15 per share, for Q1 2026, with revenues of $31,591, while cash and cash equivalents increased to $8.8 million.
0 · Reply
BongJamesBong
BongJamesBong May. 29 at 2:25 PM
$HIND From yesterday, in case you missed it. https://finance.yahoo.com/sectors/healthcare/articles/vyome-holdings-reports-first-quarter-120000113.html
0 · Reply